The duty to disclose adverse clinical trial results

S. Matthew Liao, Mark Sheehan, Steve Clarke

Research output: Contribution to journalArticle

Abstract

Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.

Original languageEnglish (US)
Pages (from-to)24-32
Number of pages9
JournalAmerican Journal of Bioethics
Volume9
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Clinical Trials
Moral Obligations
Disclosure
Informed Consent

Keywords

  • Clinical trial disclosure
  • Clinical trial registry
  • Jesse Gelsinger
  • US FDA amendments act of 2007
  • Vioxx

ASJC Scopus subject areas

  • Health Policy
  • Issues, ethics and legal aspects

Cite this

The duty to disclose adverse clinical trial results. / Liao, S. Matthew; Sheehan, Mark; Clarke, Steve.

In: American Journal of Bioethics, Vol. 9, No. 8, 08.2009, p. 24-32.

Research output: Contribution to journalArticle

Liao, S. Matthew ; Sheehan, Mark ; Clarke, Steve. / The duty to disclose adverse clinical trial results. In: American Journal of Bioethics. 2009 ; Vol. 9, No. 8. pp. 24-32.
@article{e29cbadd8f6a4ecea05c4fbcd8f4b098,
title = "The duty to disclose adverse clinical trial results",
abstract = "Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.",
keywords = "Clinical trial disclosure, Clinical trial registry, Jesse Gelsinger, US FDA amendments act of 2007, Vioxx",
author = "Liao, {S. Matthew} and Mark Sheehan and Steve Clarke",
year = "2009",
month = "8",
doi = "10.1080/15265160902984988",
language = "English (US)",
volume = "9",
pages = "24--32",
journal = "American Journal of Bioethics",
issn = "1526-5161",
publisher = "Routledge",
number = "8",

}

TY - JOUR

T1 - The duty to disclose adverse clinical trial results

AU - Liao, S. Matthew

AU - Sheehan, Mark

AU - Clarke, Steve

PY - 2009/8

Y1 - 2009/8

N2 - Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.

AB - Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.

KW - Clinical trial disclosure

KW - Clinical trial registry

KW - Jesse Gelsinger

KW - US FDA amendments act of 2007

KW - Vioxx

UR - http://www.scopus.com/inward/record.url?scp=70449614120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449614120&partnerID=8YFLogxK

U2 - 10.1080/15265160902984988

DO - 10.1080/15265160902984988

M3 - Article

C2 - 19998154

AN - SCOPUS:70449614120

VL - 9

SP - 24

EP - 32

JO - American Journal of Bioethics

JF - American Journal of Bioethics

SN - 1526-5161

IS - 8

ER -